OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
02:39 EDT 7 Aug 2012 | Bio-Medicine
BOTHELL, Wash., and VANCOUVER, British Columbia, Aug. 7, 2012 /- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that it has initiated patient enrollment in its second Phase 3 clinical trial evaluating custirsen in patients with adv..
Original Article: OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
More From BioPortfolio on "OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
